We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byTerrance Cressy
Modified over 4 years ago
© Safeguarding public health Expert Group on Innovation in the Regulation of Healthcare products Adaptive Licencing workshop at the Wellcome Trust October 15, 2012
Slide 2 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Expert Group work programme Early Access work International/comparative experience Clinical trial activity in the UK Defining the challenge in regulatory innovation -including Adaptive Licensing and developments in PV Mapping projects and initiatives -UK and US (Newdigs) Related initiatives -Advanced manufacturing regulation
Slide 3 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Developments and Action Information on flexibilities in existing licensing routes -On internet and with representative bodies -MHRA Paper Early access consultation EU proposal on Clinical Trials -Wide range of other work under the Growth Review Adaptive licensing -Initiatives and thinking on adaptive licensing -Key questions and scoping -A pilot programme of activity on adaptive licensing by Dec 2012
© Safeguarding public health Early Access
Slide 5 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Early Access Scope of the scheme -New medicines in areas of unmet need -Benefit:risk profile of the medicine must be positive -Availability restricted to predefined patient population Characteristics of the scheme -MHRA provides scientific opinion on the medicine -Medicine could be available for around 1 yr before licence granted The medicine remains unlicensed -No advertising permitted
Slide 6 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Early Access Eligible patients -Patients of any age (including children), no CT participants Eligible drugs -Restricted to any therapeutic area with un-met need Safety monitoring requirements -ADR reporting requirements will apply, additional monitoring tbd on a case by case basis
Slide 7 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Early Access Pricing -Freedom of pricing for producers of EA drugs but -NHS Trusts decide on purchase of medicine (lower cost encourages NHS uptake) Patient consent and liability issues -‘Active’ patient consent -Effective information dissemination -Manufacturer remains liable for supplying defective product Additional criteria -Benefit to UK economy -NHS funding for the medicines must be cost effective
© Safeguarding public health Adaptive Licencing
Slide 9 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Adaptive Licencing: EU / UK? Existing Legislation or not? If a UK scheme -Unlicensed use under the professional/legal responsibility of prescriber -Product for un-met need -Essentially a variant of Early Access If EU scheme -Centralised product; EU regulation applies -EMA, not UK coordinates licencing decision -European Commission will be the licensing authority Existing regulation or not? -Essentially a matter of time-frame
Slide 10 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Adaptive Licencing 3 levels of activity / tripartite structure -Level 1: EU (EMA, CHMP discussions) -Level 2: HMG/MHRA -Level 3: Industry / third sector Critical role for EU -EU licensing process -European Commission will be the licensing authority Considerable opportunities for action under current rules -Alternative means long timeframes Industry must come up with a product/asset -None identified so far – on either side of the Atlantic Merit in both retrospective and prospective work
Slide 11 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Adaptive Licencing Critical issues in regulatory decision making (risk/benefit calculation) -Evidential levels to apply -Role of RCTs – and use and interpretation of observational data Industry policy / public health policy -Industry financial/business risks / interests? Patient / professional / media understanding Wider system challenges: -Pricing / VBP -Company decisions / management of their development pipelines and processes Pilot project by end 2012
Slide 12 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © An “asset” or a product Likely characteristics: -break/-through product for as yet un-met need -Perhaps not as “open and shut” as Glivec, but not far off -Likely to be for small(er) patient population ·but not necessarily -For some of the AL ideas, possibly a product with multiple potential uses -[Probably] something with an identified patient group ·Informed consent etc
Slide 13 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Adaptive Licencing - Forward Look EU / EMA -Management Board discussion: March 2013 -CHMP and other EMA committees -Commission HMG/MHRA -Defining the pilot, and the problem(s) it is to solve -Licensing routes available -Toolbox of options -Structures and roles -Governance framework needed -Relation and link with industry/third sector support project
© Safeguarding public health Conclusions of Expert Group meeting October 9 2012: focused on Adaptive Licensing
Slide 15 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Conclusions of EG meeting, Oct 9 AL to be positioned at EU level within current legislative framework Tripartite project structure makes sense Practical programme of activity by the end of the year Need to be clear about what questions we are trying to solve Regulation, Clinical Trials, purchasing and R&D strategies within companies all relevant
Slide 16 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Work and steps ahead Commissioned papers: -Pharmacovigilance Further consideration: -EMA level work on regulatory challenge of AL -Capacity of CPRD wrt AL Pilot project for the end of the year -Retrospective and prospective activity -Identification of potential products
A 2030 framework for climate and energy policies Marten Westrup
Written Ministerial Statement DEPARTMENT OF HEALTH Practitioners of acupuncture, herbal medicine and traditional Chinese medicine Wednesday 16 February.
Overview of Risk management: A EU perspective Lincoln Tsang May 2008.
6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
1 Pension Reform in the UK: Facing the Challenges Ahead Georgina Hill British Embassy, Paris CICERO FOUNDATION SEMINAR 10 May 2007.
European Commission - Directorate General for Agriculture EU rural development policy
1 Flat-rates for indirect costs Ex-ante assessment by DG Employment, Social affairs and Equal Opportunities and DG Regional Policy Myrto Zorbala- DG Regional.
TEN-T Info Day for AP and MAP Calls 2012 EVALUATION PROCESS AND AWARD CRITERIA Anna Livieratou-Toll TEN-T Executive Agency Senior Policy & Programme Coordinator.
1 The role of macro- regional strategies after 2013 The Commissions view (or rather the view of one official) David Sweet, DG Regional Policy, European.
EU SCP/SIP Action Plan Regulatory update and insight European Economic and Social Committee Hearing, 10 December 2008, Bettina Lorz DG Environment, European.
ITU Regional Development Forum - Warsaw 7 May The Radio Spectrum Policy Programme & the Spectrum Inventory Pearse ODonohue Head of Radio Spectrum.
DEVELOPMENT OF AN INNOVATION CENTER WIPO/INN/MCT/04/3 WIPO NATIONAL WORKSHOP ON INNOVATION SUPPORT SERVICES AND THEIR MANAGEMENT Muscat, April 20, 2004.
NTA Residential Rehabilitation Event Welcome Baroness Massey of Darwen.
Good Clinical Practice in Research Clinical Trial Regulations
1 Airport of the future Spatial planning and airport development Schiphol, 30 March 2006 Mariëlle Prins, Prins Development Consultants.
Changes to the Educational Landscape: an SHA perspective Tricia Ellis, Head of Knowledge Management and eLearning South West Technology Enhanced Learning.
Findings from a survey of HGIEs in eight countries and policy implications Mutual Learning Seminar Session II: Policies to support high-growth innovative.
1 EC Ports Policy Consultation II ‘Port Service Enhancement’ ESPO General Assembly Hotel Amigo, Brussels – 7 November 2012.
© 2018 SlidePlayer.com Inc. All rights reserved.